Sinovac stock: buy or sell?
February 22nd, 2019
Sinovac Biotech Ltd., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China.
Should I buy Sinovac stock?You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. Having a trading plan helps to make decisions easier, quicker and with less hesitations. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
None of our preferred buy setups matches with Sinovac stock situation right now, hence this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Sinovac Biotech stock a buy?
Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness.Unfortunately, we couldn't find any rating for SVA stock for the last month.
Sinovac stock analysis
Sinovac shares stayed stable -0.31% to $6.47 on February.
Sinovac closed on February at $6.47 and stayed steady a lame -0.31%.
Sinovac Biotech closed this week at $6.47 and gained a tiny 0.62%. Early January SVA plummed a dreadful -5.71% in just one week.
Weekly chart tells us that price is in a simple uptrend, tested $6.30 level and now climbing back aiming its last top at $7.10.
Sinovac stock price history
Sinovac stock went public on November 3rd, 2003 with a price of $0.821. Since then, SVA stock grew a 689.00%, with an average of 45.90% per year. If you had invested $1,000 in Sinovac stock in 2003, it would worth $6,890.00 today.
1: Adjusted price after possible price splits or reverse-splits.
Sinovac stock historical price chart
SVA stock reached 52-week highs at $8.75, and all-time highs 2009-09-01 with a price of 12.5.
Sinovac stock price targetHow much a stock will be priced tomorrow or next week is quite unpredictable However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last 30 days we have not detected any price target for Sinovac stock by any trusted analyst.
Financials and fundamental analysis
Earnings date and Earnings per ShareSince last November, when Sinovac presented its last earnings report, it collapsed a scary -16.19%. Unfortunately, reported EPS is not yet available in our database.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2016, last anual revenues report draw an outstanding gain of 140.71% to $174.35 M dollars. When comparing 2017 vs 2016, aligned with this, profit margin (that is, the net income divided by revenues) boosted a 15.63% to 14.80%.
|2012||$49 M||-||$-14.85 M-30.2%||-|
|2013||$73 M||47.34%||$7.44 M10.3%||-150.10%|
|2014||$63 M||-12.99%||$-0.85 M-1.3%||-111.44%|
|2015||$67 M||6.84%||$-1.07 M-1.6%||26.20%|
|2016||$72 M||7.44%||$-0.60 M-0.8%||-44.51%|
|2017||$174 M||140.71%||$26 M14.8%||-4,430.03%|
Quarterly financial resultsReported quarter earnings marked million with a profit margin of . Profit margin remained steady a 0.00% compared to previous quarter when profit margin was nan%. When comparing revenues to same quarter last year, Sinovac sales marked a tight movement and remained steady a nan%.
|2016-Q3||$28.74 M||-||$3.21 M11.2%||-|
|2016-Q4||$31.37 M||9.15%||$4.45 M14.2%||38.81%|
Sinovac ownershipWhen you are planning to buy a stock, it's worth to have a look its ownership structure.
Sinovac shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 3.59% of all shares.
In case of Sinovac stock, 2.38% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for SVA stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to Sinovac Biotech:
|Market cap||$640.0 M||$48.2 B||$435.2 M||$198.8 B||$197.7 B|
|Total shares||98.9 M||1,270.0 M||64.0 M||4,920.0 M||2,580.0 M|
|Float shares||41.9 M||2,530.0 M||58.7 M||2,430.0 M||2,580.0 M|
|- Institutional holdings (%)||2.4%||19.4%||85.1%||11.0%||78.3%|
|- Insider holdings (%)||3.6%||0.0%||1.2%||0.0%||0.1%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Friday, February 22nd, 2019|
|Day range||$6.25 - $6.58|
|Average true range||$0.17|
|50d mov avg||$6.67|
|100d mov avg||$7.07|
|200d mov avg||$7.25|
Sinovac performanceTo better understand Sinovac performance you must compare its gains with other related stocks in same sector or industry. We selected Astrazeneca, Dynavax Technologies, GlaxoSmithKline, Merck, NewLink Genetics, NanoViricides, Novavax, Novartis and SIGA Technologies as the bechmarking frame for Sinovac Biotech stock.